Literature DB >> 11405805

Response to levodopa treatment in dopa-responsive dystonia.

J G Nutt1, T G Nygaard.   

Abstract

BACKGROUND: Dopa-responsive dystonia (DRD) is similar to Parkinson disease in that both disorders have impaired dopamine synthesis and respond to levodopa treatment. Dopa-responsive dystonia differs in that dopamine storage is intact in contrast to Parkinson disease in which it is markedly reduced.
OBJECTIVE: To examine the short- and long-duration responses to levodopa dosing in subjects with DRD.
METHODS: The response to brief infusions of levodopa was examined in 4 subjects with DRD and the effects of withdrawal of levodopa for 3 to 7 days studied in the 3 subjects receiving long-term levodopa therapy. Motor function was measured with tapping speed, Unified Parkinson's Disease Rating Scale motor score, and global dystonia score.
RESULTS: The short-duration response to levodopa dosing seems to develop more slowly and persists longer in subjects with DRD than in subjects with Parkinson disease. Withdrawal of levodopa leads to a gradual decline in tapping speed and reemergence of dystonia over several days, similar to the rate of decay of motor function in Parkinson disease. The short- and long-duration responses were not clearly differentiated in DRD.
CONCLUSIONS: This pilot study suggests that retained dopamine storage in DRD may prolong the short-duration response and blur the distinction of the short- and long-duration responses. The decline in motor function in DRD on withdrawal of long-term levodopa therapy resembles that in Parkinson disease, suggesting that a long-duration response, if it exists in DRD, is unrelated to dopamine storage.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11405805     DOI: 10.1001/archneur.58.6.905

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  8 in total

1.  Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA-induced dyskinesia in rats.

Authors:  Ayse Ulusoy; Gurdal Sahin; Deniz Kirik
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-06       Impact factor: 11.205

Review 2.  The missing, the short, and the long: Levodopa responses and dopamine actions.

Authors:  Roger L Albin; Daniel K Leventhal
Journal:  Ann Neurol       Date:  2017-06-05       Impact factor: 10.422

3.  Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats.

Authors:  Christopher Bishop; Jessica A George; William Buchta; Adam A Goldenberg; Mohamed Mohamed; Sando O Dickinson; Satie Eissa; Karen L Eskow Jaunarajs
Journal:  Eur J Neurosci       Date:  2012-07-05       Impact factor: 3.386

4.  Current and future medical treatment in primary dystonia.

Authors:  Cathérine C S Delnooz; Bart P C van de Warrenburg
Journal:  Ther Adv Neurol Disord       Date:  2012-07       Impact factor: 6.570

Review 5.  Recognizing Atypical Dopa-Responsive Dystonia and Its Mimics.

Authors:  Philippe A Salles; Mérida Terán-Jimenez; Alvaro Vidal-Santoro; Pedro Chaná-Cuevas; Marcelo Kauffman; Alberto J Espay
Journal:  Neurol Clin Pract       Date:  2021-12

Review 6.  The Human Experience with Intravenous Levodopa.

Authors:  Shan H Siddiqi; Natalia K Abraham; Christopher L Geiger; Morvarid Karimi; Joel S Perlmutter; Kevin J Black
Journal:  Front Pharmacol       Date:  2016-01-06       Impact factor: 5.810

7.  Neurophysiological assessment of juvenile parkinsonism due to primary monoamine neurotransmitter disorders.

Authors:  Massimiliano Passaretti; Luca Pollini; Giulia Paparella; Alessandro De Biase; Donato Colella; Luca Angelini; Serena Galosi; Filippo Manti; Andrea Guerra; Vincenzo Leuzzi; Alfredo Berardelli; Matteo Bologna
Journal:  J Neural Transm (Vienna)       Date:  2022-07-12       Impact factor: 3.850

8.  The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa.

Authors:  Roberto Cilia; Albert Akpalu; Fred Stephen Sarfo; Momodou Cham; Marianna Amboni; Emanuele Cereda; Margherita Fabbri; Patrick Adjei; John Akassi; Alba Bonetti; Gianni Pezzoli
Journal:  Brain       Date:  2014-07-17       Impact factor: 13.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.